Bind and Amgen complete research program

Citing results that were not compelling enough to proceed, Bind Therapeutics (BIND -3.4%) and Amgen (AMGN +0.6%) notify each other that they will not be exercising their options to develop an Accurin incorporating the Amgen therapeutic payload. 

The collaboration began in January 2013 with the goal of developing a nanomedicine for treating solid cancer tumors based on Bind's platform for targeted and programmable nanomedicines and Amgen's undisclosed proprietary cancer compound. 

Bind CEO Scott Minick says that his company will proceed undeterred with its collaborations with AstraZeneca (AZN +2%), Roche (RHHBY -0.6%) and Pfizer (PFE +1%). 

From other sites
Comments (1)
  • sunwindgeo
    , contributor
    Comments (856) | Send Message

    Nightly business report, July 2, 2014, could adversely impact PFE stock. Their pills (Lipitor) not same for US and foreign markets, and not clear they are even Lipitor for US buyers at pharmacies. (Probably has to do with competition amongst pharmacies like Walgreen, CVS, etc., motivations to find cheaper drugs, increase profits).
    3 Jul 2014, 07:33 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs